Phanes Therapeutics Receives FDA Fast Track Designation for Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma

RegulatorySpevatamigPositive

AI Analysis

Summary

Phanes Therapeutics received FDA Fast Track Designation for Spevatamig, an anti-CLDN18.2/CD47 bispecific antibody in Phase 2 development for advanced and metastatic biliary tract carcinoma. The designation recognizes the drug as an innate immunity enhancer with potential for multiple gastrointestinal cancer indications.

Clinical Trial Data

Phase

Phase 2

Outcome Details

FDA Fast Track Designation granted

Importance:6/10

Sentiment:

0.70

FDA Fast TrackImmuno-oncologyBispecific antibodyGastrointestinal cancerBiliary tract carcinoma

Related Companies

$DFPH $IPH.PA

Read the original article

Published by PR Newswire Pharma on August 14, 2026 2:00 PM

Read Original